ArticleAdvances in therapy2021
Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims.
Article in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Epidemiology and burden of alopecia areata in Taiwan: a systematic review.Frontiers in medicine · 2025Pooled it
- Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.American journal of clinical dermatology · 2023Pooled it
- Anxiety, depression, and quality of life in children and adults with alopecia areata: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey.Dermatology and therapy · 2026Article
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA.Dermatology and therapy · 2026Article
- Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.Dermatology and therapy · 2026Article
- Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA.Dermatology and therapy · 2026Article
- Ophthalmologic Comorbidities in Alopecia Areata.Journal of clinical medicine · 2025Review
- Article
- Prevalence of Thyrotropin Receptor Antibodies and Clinical Profile of Patients with Alopecia Areata: A Cross-Sectional Study.Skin appendage disorders · 2025Article
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database.The Journal of dermatology · 2024Article
- Subclinical Atherosclerosis in Alopecia Areata: Usefulness of Arterial Ultrasound for Disease Diagnosis and Analysis of Its Relationship with Cardiometabolic Parameters.Journal of clinical medicine · 2024Article
- Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries.Dermatology and therapy · 2024Article
- Patients' experiences of primary healthcare and dermatology provision for alopecia.Skin health and disease · 2024Article
- Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis.Acta dermato-venereologica · 2023Article
- Overview of alopecia areata for managed care and payer stakeholders in the United States.Journal of managed care & specialty pharmacy · 2023Article
- Baricitinib: A Review in Severe Alopecia Areata.American journal of clinical dermatology · 2023Review
- Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women.Archives of dermatological research · 2023Article
- Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective.Journal of managed care & specialty pharmacy · 2023Article
- Recent advances in the genetics of alopecia areata.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
introductionAlopecia areata (AA) is an autoimmune disorder causing sudden, non-scarring hair loss. There are currently no drugs approved for AA treatment. This study assessed prevalence of comorbidities, treatments, and healthcare costs and resource utilization among patients with AA in the USA.
methodsPatients diagnosed with AA between January 2011 and December 2018 were identified in IBM MarketScan
resultsA total of 68,121 patients with AA were identified. Mean (SD) age was 40.3 (17.8) years and 61.0% were female. The most common comorbidities included hyperlipidemia (22.4%), hypertension (21.8%), thyroid disorders (13.1%), contact dermatitis or eczema (10.8%), depression (9.5%), and anxiety (8.4%). Comorbid autoimmune diseases included atopic dermatitis (2.8%), psoriasis (2.1%), chronic urticaria (1.5%), and rheumatoid arthritis (1.1%). During the 12-month follow-up period, 37,995 patients (55.8%) were prescribed treatment for their AA or other comorbid autoimmune/inflammatory disease; 44.9% of treated patients were prescribed therapy within 7 days of AA diagnosis. Of patients receiving treatment, 80.3% received topical steroids and 30.0% received oral steroids. Mean (SD) total healthcare costs were $11,241.21 ($43,839.69) for all-causes and $419.12 ($1534.99) for AA. AA-related expenses were driven by outpatient and prescription costs.
conclusionPatients with AA have a high comorbidity burden and lack of treatment. Current AA treatments, including systemic therapies other than oral steroids, were not frequently utilized in this study population. Healthcare costs incurred by patients with AA went beyond AA-related expenses. Longitudinal data are needed to better understand treatment trajectories and the disease burden in patients with AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.